Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 51540
Gene Symbol: SCLY
SCLY
0.010 Biomarker disease BEFREE The aim of this pilot study was to determine health-related quality of life (HRQoL) in patients with history of medication overuse headache (MOH) after detoxification and a headache-specific inpatient rehabilitation program and to receive necessary information for future prospective studies.HRQoL and headache-related disability were cross-sectionally measured by Short Form 36 (SF-36), Hospital Anxiety and Depression Scale (HADS), Migraine Disability Score (MIDAS), Coping Strategies Questionnaire (CSQ), and Symptom Checklist 90 revised (SCL-90-R). 29381924 2017
Entrez Id: 10267
Gene Symbol: RAMP1
RAMP1
0.010 GeneticVariation disease BEFREE When genotype distribution for RAMP1 rs7590387 was compared between healthy controls (n = 209) and MOH patients, carriers of rs7590387GG were found at lower risk of developing MOH (OR: 0.43, 95%CI: 0.22-0.85, P = 0.011). 25881990 2015
Entrez Id: 8841
Gene Symbol: HDAC3
HDAC3
0.010 GeneticVariation disease BEFREE In this association study, we sequenced all exons, intron/exon junctions, and 3'-5'UTR regions of HDAC3 in 23 MOH patients to investigate its role in medication overuse. 26542778 2015
Entrez Id: 6506
Gene Symbol: SLC1A2
SLC1A2
0.010 Biomarker disease BEFREE In the present study, we aimed to evaluate the role of 14 polymorphisms in 8 candidate genes potentially relevant for drug addiction (OPRM1, DRD2, DBH, COMT, BDNF, SLC6A4, 5HT2A, and SLC1A2) as predictors for detoxification outcome of MOH patients at 2 months of follow-up. 25096645 2014
Entrez Id: 1312
Gene Symbol: COMT
COMT
0.010 GeneticVariation disease BEFREE Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. 24684248 2014
Entrez Id: 4524
Gene Symbol: MTHFR
MTHFR
0.010 GeneticVariation disease BEFREE By multivariate logistic stepwise regression analysis, type of migraine, regular and sufficient dietary intake, and methylenetetrahydrofolate reductase (MTHFR) C677T (rs1801133) and dopamine D2 receptor (DRD2) rs6275" genes_norm="1813">C939T (rs6275) polymorphisms were selected as significant factors that contribute independently to the development from migraine to MOH (P < 0.05). 22290307 2013
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.010 GeneticVariation disease BEFREE We therefore sought differences in SSEP sensitization and habituation in patients with MOH who underwent angiotensin converting enzyme (ACE) I/D polymorphism analysis. 23053304 2012
Entrez Id: 3355
Gene Symbol: HTR1F
HTR1F
0.010 GeneticVariation disease BEFREE In conclusion, our studydoes not provide evidence that the 5HTT, 5-HT1A, 5HT1B,5HT2A and 5HT6 gene polymorphisms play a role in the genetic predisposition to MOH. 19936617 2010
Entrez Id: 3350
Gene Symbol: HTR1A
HTR1A
0.010 GeneticVariation disease BEFREE In conclusion, our studydoes not provide evidence that the 5HTT, 5-HT1A, 5HT1B,5HT2A and 5HT6 gene polymorphisms play a role in the genetic predisposition to MOH. 19936617 2010
Entrez Id: 627
Gene Symbol: BDNF
BDNF
0.010 GeneticVariation disease BEFREE These findings showed an influence of examined BDNF polymorphism in the MOH clinical features, supporting the idea that MOH is a substance abuse disorder. 19517061 2009
Entrez Id: 7466
Gene Symbol: WFS1
WFS1
0.010 Biomarker disease BEFREE These results implicate WFS1 in the clinical picture of MOH, may be through an influence on need for drugs as in other conditions of abuse behaviour. 17719176 2007